Literature DB >> 16079123

Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma.

Andrew Wei, David Westerman, Frank Feleppa, Melanie Trivett, Surender Juneja.   

Abstract

Plasma cell microaggregates detected by CD138 immunohistology were demonstrated in 22% of patients achieving morphologic remission 3 months after high-dose therapy for myeloma. Microaggregates were predictive of earlier disease progression, indicating that immunohistology may represent a useful tool in the assessment of minimal disease in patients after high-dose therapy for myeloma.

Entities:  

Mesh：

Year:  2005        PMID： 16079123

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  5 in total

1.  Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.

Authors:  Samer Z Al-Quran; Lijun Yang; James M Magill; Raul C Braylan; Vonda K Douglas-Nikitin
Journal:  Hum Pathol       Date:  2007-08-21       Impact factor: 3.466

Review 2.  What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.

Authors:  Scott Ely; Noa Biran; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

3.  Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.

Authors:  Sanja Stifter; Emina Babarović; Toni Valković; Irena Seili-Bekafigo; Christophe Stemberger; Antica Nacinović; Ksenija Lucin; Nives Jonjić
Journal:  Diagn Pathol       Date:  2010-05-18       Impact factor: 2.644

4.  Rapid in-situ hybridization and immunohistochemistry: a pilot comparative study of two rapid diagnostic techniques for establishing monoclonality in plasma cell dyscrasias.

Authors:  Arijit Sen; Divya Gupta; Rajat Jagani
Journal:  Med J Armed Forces India       Date:  2019-04-05

5.  Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.

Authors:  M Espiño; A Arteche-López; S Medina; C Muñoz-Calleja; M J Blanchard; A Alegre; F J López-Jiménez; L M Villar
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.